[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].

Takuya Hamakawa, Yukinori Kurokawa, Shuji Takiguchi, Tsuyoshi Takahashi, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Masaki Mori, Yuichiro Dok

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Combination of docetaxel, cisplatin, and S-1 (DCS) is expected as a new treatment regimen for far advanced gastric cancer. We performed DCS chemotherapy for six patients, including four cases with invasion to pancreas, three cases with para-aortic lymph node metastasis, and two cases with liver metastasis. Clinical stages were either IIIC or IV for all of the patients. The patients received 2-4 courses of docetaxel (40 mg/m2) and cisplatin (60 mg/m2) on day 1, and S-1 (80 mg/m2) on days 1-14 every 4 weeks. The response rate was 83% (5 PR and 1 SD), and the disease control rate was 100%. Grade 3/4 neutropenia, grade 3 febrile neutropenia, and grade 3 diarrhea were observed in three cases (50%), one case (17%), and one case (17%), respectively. Four of six patients underwent R0 surgery after DCS chemotherapy, and no severe complication was occurred. Histological responses were Grade 2 for two cases, Grade 1b for one case, and Grade 1a for one case, respectively. DCS regimen showed a high objective tumor response, and also is one of the promising regimens as neoadjuvant setting for far advanced gastric cancer.

Original languageEnglish
Pages (from-to)2342-2344
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number12
Publication statusPublished - Nov 2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of '[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].'. Together they form a unique fingerprint.

Cite this